Molecular risk to formation pathway. Acceptable intake to batch result. Mitigation to market implementation.

Nitrosamine control is a portfolio-scale knowledge and evidence problem. Risk can originate in API synthesis, recovered solvents, reagents, excipients, water, cross-contamination, packaging, storage, or an API's own amine structure. Acceptable intakes and technical expectations evolve, while one supplier or formulation change can alter conclusions across many products and markets.

Seal connects molecular and process knowledge to product-specific risk, analytical evidence, patient exposure, mitigation, filings, inventory, and ongoing review. It preserves assumptions so a revised limit or newly understood pathway identifies every dependent decision.

API, salt, fragment, dosage form, strength, route, maximum daily dose, duration, formulation, manufacturing and packaging sites, API and excipient sources, process versions, markets, application status, and product lifecycle state define scope.

Assessment status distinguishes screened, potentially at risk, confirmatory testing required, mitigated, controlled, temporarily accepted, and under reassessment.

Name, synonyms, structure, formula, identifiers, precursor relationship, API structural similarity, NDSRI classification, physicochemical properties, standards, analytical response, toxicological data, predicted potency category, acceptable intake, interim limit, and source authority remain versioned.

One compound can have different conclusions by route, duration, product, jurisdiction, or evolving authority position.

Amine or susceptible structure, nitrite or other nitrosating source, pH, solvent, catalyst, temperature, water activity, oxygen, time, sequence, concentration, quench, recycle, degradation, packaging, storage, and cross-contamination create a pathway.

Each pathway identifies evidence for presence, absence, prevention, purge, or uncertainty and the process stages and products it can affect.

API starting materials and intermediates, reagents, recovered solvents, water, catalysts, quench agents, excipients, printing or packaging materials, cleaning residues, shared equipment, and supplier processes retain amine and nitrite knowledge, test evidence, limits, variability, and change obligations.

A compendial excipient grade does not automatically establish a suitably low nitrite contribution for every formulation.

Pathway plausibility, precursor levels, process conditions, purge or clearance, equipment and campaign history, contamination controls, formulation, package, storage, dose, duration, analytical capability, prior results, supplier controls, and uncertainty determine the conclusion.

Seal preserves cited evidence and calculations rather than reducing the assessment to a questionnaire answer.

Authority source, publication date, compound, structural features, predicted category, compound-specific data, read-across, interim or final status, duration adjustment where applicable, numerical limit, units, rationale, reviewer, effective date, and supersession define the limit.

A limit update automatically identifies affected specifications, methods, results, products, markets, filings, inventory, and prior decisions.

Acceptable daily intake, maximum daily dose, dosage units, strength, conversion factors, analytical reporting basis, combination of multiple nitrosamines, rounding, uncertainty, and applicable market create concentration or per-unit limits.

Every product-limit version retains inputs and the inventory population to which it applies.

Screening, targeted confirmatory testing, multi-analyte methods, NDSRI-specific methods, formation studies, excipient or API testing, stability monitoring, and investigations identify matrix, compounds, sensitivity, selectivity, interferences, recovery, standards, controls, sample preparation, and intended decision.

Method capability is evaluated against product-specific limits, not a generic reporting threshold.

Reference identity, purity, correction, preparation, storage, expiry, stability, calibration, internal standard, instrument method, acquisition, chromatogram or spectrum, integration, qualifier ions or transitions, blanks, carryover, system suitability, audit trail, and review remain attributable.

Seal connects SDMS evidence to results while retaining every reintegration, exclusion, repeat, and calculation.

API and product batches, strengths, sites, material suppliers, process versions, packaging, manufacture dates, storage ages, conditions, bracketing, sample selection, pooling restrictions, methods, results, and uncertainty define the program.

Selection rationale remains visible. One conveniently available batch cannot represent a diverse global portfolio without justification.

Measured concentration, units, sample basis, recovery or correction, uncertainty, daily dose, dosing frequency, multiple strengths or products, duration, and current acceptable intake calculate exposure and margin.

Below quantitation, estimated, confirmed, invalid, and not tested states stay distinct.

Long-term, accelerated, stress, in-use, temperature excursion, light, moisture, oxygen, package, headspace, formulation, antioxidant or inhibitor, timepoint, compound, and result reveal formation or degradation behavior.

Shelf-life models and proposed mitigations retain supporting batches, fit, uncertainty, and limits; they cannot hide a late increasing trend.

Supplier control, tighter nitrite or amine limits, raw-material testing, solvent or reagent change, process sequence, pH, temperature, quench, purge, cleaning, dedicated equipment, formulation, antioxidant, package, storage, shelf life, or analytical control connects to the pathway it interrupts.

Feasibility, development, validation, comparability, stability, bioequivalence, supply, filing, and implementation dependencies remain one plan.

API lots, drug-product batches, strengths, markets, locations, status, results, expiry, distributed quantity, shortage considerations, interim control, retest, rework where permitted, release, hold, rejection, or recall assessment connect to the effective limit and control strategy.

A market action can be scoped without changing the scientific record for unaffected products.

Risk-assessment completion, confirmatory findings, method and validation, root cause, mitigation, timelines, annual-report or supplement strategy, authority questions, commitments, shortage communication, and implementation state resolve by application and market.

The system distinguishes guidance recommendations, approved commitments, and internal targets.

API route, recovered solvent, raw-material source, excipient site or composition, nitrite level, packaging, process, specification, analytical method, or quality-agreement change traverses every pathway and product that used the prior knowledge.

Changed evidence can narrow or expand risk without recreating assessments manually.

New compounds, structural alerts, acceptable-intake updates, analytical advances, supplier knowledge, internal results, stability trends, authority communications, recalls, scientific publications, product changes, and control performance trigger reassessment.

The review records what changed, which assumptions remain valid, impacted products, actions, owners, due dates, and completion evidence.

Seal is strongest across chemistry, toxicology, suppliers, analytical laboratories, manufacturing, stability, quality, regulatory, inventory, and market action. It owns the dependency graph from scientific assumption to product decision.

The first implementation should follow an API with secondary amine functionality through route and supplier assessment, excipient nitrite data, NDSRI pathway, acceptable-intake rationale, product-limit calculation, method development and validation, representative testing, increasing stability trend, mitigation, market filings, inventory controls, and periodic reassessment.

Include an updated AI, an unknown supplier nitrite range, a below-LOQ result, a confirmed late-shelf-life finding, a reformulation, one market using an interim limit, and a batch already distributed. The system must recompute every affected decision without losing the historical basis.